Plasma metabolome analysis of patients with major depressive disorder
Psychiatry and Clinical Neurosciences Feb 01, 2018
Kawamura N, et al. - Researchers here delineated the plasma metabolite profiling of patients with major depressive disorder (MDD). Findings suggested that in the clinical setting, plasma phosphoethanolamine (PEA) level could be a candidate biomarker of MDD.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries